This Vaccine Research Update highlights major progress across infectious disease and oncology vaccine programs. CEPI is accelerating three Bundibugyo ebolavirus vaccine candidates in response to an ongoing outbreak. Moderna and Merck report durable five-year survival benefits from their personalized melanoma vaccine combination. Early-stage clinical activity includes Idorsia’s C. difficile vaccine, Vaxcyte’s Group A Streptococcus program, and first-in-human data for a universal coronavirus vaccine. Additional updates cover SK bioscience’s rotavirus program, Invivyd’s Phase 3 COVID-19 vaccine trial, and Rwanda’s multinational chikungunya vaccine consortium, reflecting broad global momentum in vaccine innovation and development.